Charles River And AAVantgarde Ink CDMO Contract To Produce Good Manufacturing Practice-Plasmid DNA
Portfolio Pulse from Benzinga Newsdesk
Charles River Laboratories International, Inc. (NYSE:CRL) and AAVantgarde have signed a CDMO agreement to produce GMP plasmid DNA for AAVantgarde's Stargardt's disease program. This collaboration leverages Charles River's expertise in manufacturing and AAVantgarde's proprietary AAV vector platforms.
July 08, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Charles River Laboratories International, Inc. (NYSE:CRL) has entered into a CDMO agreement with AAVantgarde to produce GMP plasmid DNA for AAVantgarde's Stargardt's disease program. This partnership highlights CRL's expertise in manufacturing and could enhance its reputation and business in the biotech sector.
The partnership with AAVantgarde to produce GMP plasmid DNA for a high unmet need ophthalmology indication could boost Charles River's business and reputation in the biotech sector. This collaboration leverages CRL's manufacturing expertise, potentially leading to increased demand for its services.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80